Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group Protocol 91-06

Journal of Clinical Oncology

Volumn 14, Issue 4, 1996, Pages 1055-1064

  Lee, J S ^a   Scott, C ^a   Komaki, R ^a   Fossella, F V ^a   Dundas, G S ^a   McDonald, S ^a   Byhardt, R W ^a   Curran Jr , W J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUOROURACIL; LOMUSTINE; VINBLASTINE; VINDESINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; ESOPHAGITIS; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE FRACTIONATION; TREATMENT OUTCOME;

EID: 0029966671     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.4.1055     Document Type: Article

References (61)

1. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995. CA 45:8-30, 1995
2. Ihde DC, Minna JD: Non-small cell lung cancer. Part II: Treatment. Curr Prob Cancer 15:105-154, 1991
3. Perez C, Stanley K, Grundy G, et al: Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung. Cancer 50:1091-1099, 1982
4. Petrovich Z, Stanley K, Cox J, Paige C: Radiotherapy and the management of locally advanced lung cancer of all cell types. Final report of randomized trial. Cancer 48:1335-1340, 1981
5. Coy P, Kenelly G: The role of curative radiotherapy in treatment of lung cancer. Cancer 45:698-702, 1980
6. Sealy R, Lagakoss, Barkley T, et al: Radiotherapy of regional epidermoid carcinoma of the lung: A study in fractionation. Cancer 49:1338-1345, 1982
7. Holsti LR, Mattson K: A randomized study of split-course radiotherapy of lung cancer: Long term results. Int J Radiat Oncol Biol Phys 6:977-981, 1980
8. Katz MR, Alberts RW: A comparison of high-dose continuous and split-course irradiation in non-oat cell carcinoma of the lung. Am J Clin Oncol 6:445-457, 1983
9. Choi NCH, Doucette JA: Improved survival of patients with unresectable non-small cell bronchogenic carcinoma by an innovated high-dose en bloc radiotherapeutic approach. Cancer 48:101-109, 1981
10. Cox JD, Azarnia N, Byhardt RW, et al: A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with ≥ 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: Report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 8:1543-1555, 1990
11. Saunders MI, Dische S, Grosch EJ, et al: Experience with CHART. Int J Radiat Oncol Biol Phys 21:871-878, 1991
12. Ihde DC: Chemotherapy combined with chest irradiation for locally advanced non-small cell lung cancer. Ann Intern Med 115:737-739, 1991
13. Shaw EG, McGinnis WL, Jett JR, et al: Pilot study of accelerated hyperfractionated thoracic radiation therapy plus concomitant etoposide and cisplatin chemotherapy in patients with unresectable stage III non-small cell carcinoma of the lung. J Natl Cancer Inst 85:321-323, 1993
14. Umsawasdi T, Valdivieso M, Barkley HT, Jr, et al: Combined chemoradiotherapy in limited-disease, inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 14:43-48, 1988
15. Friess GG, Baikadi M, Harvey WH: Concurrent cisplatin and etoposide with radiotherapy in locally advanced non-small cell lung cancer. Cancer Treat Rep 71:681-684, 1987
16. Sause WT, Scott C, Taylor S, et al: Phase II trial of combination chemotherapy and irradiation in non-small cell lung cancer, Radiation Therapy Oncology Group 88-04. Am J Clin Oncol 15:163-167, 1992
17. Dillman RO, Seagren SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940-945, 1990
18. LeChevalier T, Arriagada R, Quoix E, et al: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417-423, 1991
19. LeChevalier T, Arriagada R, Tarayre M, et al: Significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung cancer. J Natl Cancer Inst 84:58, 1992 (letter)
20. Schaake-Koning C, van den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530, 1992
21. Sause WT, Scott C, Taylor S, et al: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87:198-205, 1995
22. Jeremic B, Shibamoto Y, Acimovic L, et al: Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13:452-458, 1995
23. Mattson K, Holsti LR, Holsti P, et al: Inoperable non-small cell lung cancer: Radiation with or without chemotherapy. Eur J Cancer Clin Oncol 24:477-482, 1988
24. VanHoutte P, Klastersky J, Renaud A, et al: Introduction chemotherapy with cisplatin, etoposide and vindesine before radiation therapy for non small-cell lung cancer. A randomized study. Antibiot Chemother 41:131-137, 1988
25. Trovo MG, Mintel E, Veronesi A, et al: Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma. Cancer 65:400-404, 1990
26. Morton RF, Jett JR, McGinnis WL, et al: Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. Ann Intern Med 115:681-686, 1991
27. Trovo MG, Minatel E, Franchin G, et al: Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 24:11-15, 1992
28. Gregor A, Macbeth FR, Paul J, et al: Radical radiotherapy and chemotherapy in localized inoperable non-small cell lung cancer: A randomized trial. J Natl Cancer Inst 85:997-999, 1993
29. Perez CA, Stanley K, Rubin P, et al: Patterns of tumor recurrence after definitive irradiation for inoperable non-oat cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 6:987-994, 1980
30. Schabel FM, Trader MW, Laster WR, et al: cis-Dichlorodiammine-platinum (II) combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 63:1459-1473, 1979
31. Sierocki JS, Hilaris BS, Hopfan S, et al: cis-Dichlorodiammineplatinum (II) and VP-16-213: An active induction regimen for small cell carcinoma of the lung. Cancer Treat Rep 63:1593-1597, 1979
32. Evans WK, Shepherd FA, Feld R, et al: VP-16 and cisplatin as first-line therapy for small cell lung cancer. J Clin Oncol 3:1471-1477, 1985
33. Goldhirsch A, Joss RA, Cavalli F, et al: Cis-dichlorodiammine-platinum (II) and VP-16-213 combination chemotherapy for non-small cell lung cancer. Med Pediatr Oncol 9:205-208, 1981
34. Longeval E, Klastersky J: Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma: A study by the EORTC Lung Cancer Working Party (Belgium). Cancer 50:2751-2756, 1982
35. Zak M, Drobnik J: Effect of cis-dichlorodiammineplatinum (II) on the post-irradiation lethality in mice after irradiation with x-rays. Strahlentherapie 142:112-115, 1971
36. Wodkinsky II, Swiniarski J, Kensler CJ, et al: Combination radiotherapy and chemotherapy for P388 lymphocytic leukemia in vitro. Cancer Treat Rep 4:73, 1974
37. Richmond RC, Zimbrick JD. Hykes DL: Radiation induced DNA damage and lethality in E. coli as modified by the antitumor agent cis-dichlorodiammineplatinum (II). Radiat Res 71:447-460, 1977
38. Douple EB, Richmond RC, Logan ME: Therapeutic potentiation in a mouse mammary tumor and an intracerebral rat brain tumor by combined treatment with cis-dichlorodiammineplatinum (II) and radiation. J Clin Hematol Oncol 7:585-603, 1977
39. Soloway MS, Morris CR, Sudderth B: Radiation therapy and cis-diamminedichloroplatinum (II) in transplantable and primary murine bladder cancer. Int J Radiat Oncol Biol Phys 5:1355-1360, 1979
40. Szumiel I, Nias AHW: The effect of combined treatment with a platinum complex and ionizing radiation on Chinese hamster ovary cells in vitro. Br J Cancer 33:450-458, 1976
41. Evans HH, Ricanati M, Horng M, Menel J: Relationship between topoisomerase II and radiosensitivity in mouse L5178Y lymphoma strains. Mutat Res 217:53-63, 1989
42. Slevin ML, Clark PI, Joel SP, et al: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7:1333-1340, 1989
43. Hainsworth JD, Johnson DH, Frazier SR, et al: Chronic daily administration of oral etoposide - A phase I trial. J Clin Oncol 7:396-401, 1989
44. Johnson DH, Strupp J, Greco FA, et al: Prolonged administration of oral etoposide in previously treated small cell lung cancer patients: a phase II trial. Proc Am Soc Clin Oncol 9:227, 1990 (abstr)
45. Einhorn LH, Pennington K, McClean J: Phase II trial of daily oral VP-16 in refractory small cell lung cancer: A Hoosier Oncology Group study. Semin Oncol 17:32-35, 1990 (suppl 2)
46. Waits TM, Johnson DH, Hainsworth JD, et al: Prolonged administration of oral etoposide in non-small-cell lung cancer: A phase II trial. J Clin Oncol 10:292-296, 1992
47. Mountain CF: A new international staging system for lung cancer. Chest 89:225S-233S, 1986 (suppl)
48. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
49. Mehta C, Patel N: Stat Xact, Cambridge, MA, Cytel Software, 1992
50. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
51. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
52. Caplan RJ, Pajak TF, Cox JD: Analysis of the probability and risk of cause specific failure. Int J Radiat Oncol Biol Phys 29:1183-1186, 1994
53. Dixon WJ: BMDP Statistical Software Manual. Berkley, CA, University of California Press, 1992
54. Weiden PL, Piantadosi S, Lung Cancer Study Group (LCSG): Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small cell lung cancer: A phase II study of the LCSG. J Natl Cancer Inst 83:266-272, 1991
55. Strauss GM, Herndon JE, Sherman DD, et al: Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinomas of the lung: Report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 10:1237-1244, 1992
56. Albain K, Rusch J, Crowley A, et al: Concurrent cisplatin/ etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13:1880-1892, 1995
57. Dillman RO, Seagren SL, Herndon J, et al: Randomized trial of induction chemotherapy plus radiation therapy vs. RT alone in stage III non-small lung cancer (NSCLC): Five-year follow-up of CALGB 84-33. Proc Am Soc Clin Oncol 12:329, 1993 (abstr)
58. Sause W, Scott C, Byhardt R, et al: Recursive partitioning analysis of 1,592 patients on four RTOG studies in non-small cell lung cancer. Proc Am Soc Clin Oncol 12:336, 1993 (abstr)
59. Sause WT, Scott C, Taylor S, et al: RTOG 8808 ECOG 4588, Preliminary analysis of a phase III trial in regionally advanced unresectable non-small cell lung cancer with minimum three year follow-up. Int J Radiat Oncol Biol Phys 32:195, 1995 (suppl 1, abstr)
60. McGinnis WL, Shaw EG, Jung S-H, et al: Results of a phase III prospective randomized trial comparing standard thoracic radiation therapy (TRT) to twice-daily (BID) TRT +/- concomitant etoposide-cisplatin (EP) chemotherapy in patients with unresectable stage IIIA/B non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:355, 1995 (abstr)
61. Goldie JG, Coldman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727-1733, 1979